, Volume 224, Issue 2, pp 255–262 | Cite as

The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats

  • Kristin M. Alvers
  • Joshua S. Beckmann
  • Guangrong Zheng
  • Peter A. Crooks
  • Linda P. Dwoskin
  • Michael T. Bardo
Original Investigation



The vesicular monoamine transporter 2 (VMAT2) has been identified as a potential target for the treatment of methamphetamine (METH) abuse. GZ-793A is a potent and selective VMAT2 inhibitor that has been shown to block the primary and conditioned reinforcing effects of METH, while demonstrating no abuse liability when given alone.


The aim of the current study was to determine if GZ-793A attenuates METH- or cue-induced reinstatement of METH-seeking after a period of extinction. The effect of acute GZ-793A on locomotor activity also was assessed.


After a period of extinction, rats were administered GZ-793A (15 mg/kg, s.c.) 15 min prior to a priming injection of METH or re-exposure to cues associated with METH infusions. GZ-793A also was administered 20 min prior to an injection of METH (0.5 mg/kg, s.c.) or saline to determine its effect on locomotor behavior.


Pretreatment with GZ-793A (15 mg/kg) decreased cue-induced reinstatement, without demonstrating any response suppressive effects when administered in the absence of reinstating stimuli. GZ-793A also decreased methamphetamine-induced reinstatement; however, response suppressant effects of GZ-793A were obtained when the compound was presented alone. In this latter experiment, GZ-793A may have reduced responding for the conditioned reinforcing effects of the contingently available cues rather than having nonspecific effects on baseline responding. GZ-793A had no effect on locomotor activity when administered alone or with METH.


GZ-793A and related VMAT2 inhibitors may be promising leads for reducing the risk of relapse to METH use following exposure to drug-associated cues.


Methamphetamine Reinstatement Relapse GZ-793A VMAT2 Locomotor activity 



This research was supported by the National Institute of Drug Abuse grants DA13519 and DA016176. We thank Emily Denehy for technical assistance. The University of Kentucky holds a patent on GZ-793A, and a potential royalty stream to LPD, GZ, and PAC may occur consistent with the University of Kentucky policy.

Conflict of interest

The other authors have no disclosures.


  1. Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT (2012) The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl) 220:395–403Google Scholar
  2. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y (2005) Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526:36–50PubMedCrossRefGoogle Scholar
  3. Carroll ME, Lac ST (1993) Autoshaping i.v. cocaine self-administration in rats: effects of nondrug alternative reinforcers on acquisition. Psychopharmacology (Berl) 110:5–12Google Scholar
  4. Community Epidemiology Work Group (2009) Proceedings of the Community Epidemiology Work Group: Volume I. Highlights and Executive Summary (NIH Publication No. 10-7421). Bethesda, MDGoogle Scholar
  5. Di Ciano P, Blaha CD, Phillips AG (1998) The relationship between dopamine oxidation currents in the nucleus accumbens and conditioned increases in motor activity in rats following repeated administration of d-amphetamine or cocaine. Eur J Neurosci 10:1113–1120PubMedCrossRefGoogle Scholar
  6. Di Ciano P, Blaha CD, Phillips AG (2001) Changes in dopamine efflux associated with extinction, CS-induced and d-amphetamine-induced reinstatement of drug-seeking behavior by rats. Behav Brain Res 120:147–158PubMedCrossRefGoogle Scholar
  7. Dwoskin LP, Crooks PA (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 63:89–98PubMedCrossRefGoogle Scholar
  8. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008) Pharmacology of methamphetamine addiction: an update. Subst Abus 29:31–49PubMedCrossRefGoogle Scholar
  9. Gratton A, Wise RA (1994) Drug- and behavior-associated changes in dopamine-related electrochemical signals during intravenous cocaine self-administration in rats. J Neurosci 14:4130–4146PubMedGoogle Scholar
  10. Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39:149–170PubMedCrossRefGoogle Scholar
  11. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, Bardo MT (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 298:172–179PubMedGoogle Scholar
  12. Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, Bardo MT (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) 165:397–404Google Scholar
  13. Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther 339:286–297PubMedCrossRefGoogle Scholar
  14. Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ (2000) Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J Neurosci 20:7489–7495PubMedGoogle Scholar
  15. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (2010) Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 69:578–592PubMedCrossRefGoogle Scholar
  16. Kiyatkin EA, Stein EA (1996) Conditioned changes in nucleus accumbens dopamine signal established by intravenous cocaine in rats. Neurosci Lett 211:73–76PubMedCrossRefGoogle Scholar
  17. Meyer AC, Horton DB, Neugebauer NM, Wooters TE, Nickell JR, Dwoskin LP, Bardo MT (2011) Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology 61:849–856PubMedCrossRefGoogle Scholar
  18. Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, Dwoskin LP (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 296:1023–1034PubMedGoogle Scholar
  19. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP (2004) Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicula monoamine transporters. J Pharmacol Exp Ther 310:1035–1045PubMedCrossRefGoogle Scholar
  20. Neisewander JL, O’Dell LE, Tran-Nguyen LT, Castañeda E, Fuchs RA (1996) Dopamine overflow in the nucleus accumbens during extinction and reinstatement of cocaine self-administration behavior. Neuropharmacology 15:506–514Google Scholar
  21. Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT (2007) Lobelane decreases methamphetamine self-administration in rats. Eur J Pharmacol 571:33–38PubMedCrossRefGoogle Scholar
  22. Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP (2009) Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther 332:612–621PubMedCrossRefGoogle Scholar
  23. O’Brien CP (1997) A range of research-based pharmacotherapies for addiction. Science 278:66–70PubMedCrossRefGoogle Scholar
  24. Ramo DE, Brown SA (2008) Classes of substance abuse relapse situations: a comparison of adolescents and adults. Psychol Addict Behav 22:372–379PubMedCrossRefGoogle Scholar
  25. Ranaldi R, Pocock D, Zereik R, Wise RA (1999) Dopamine fluctuations in the nucleus accumbens during maintenance, extinction, and reinstatement of intravenous D-amphetamine self-administration. J Neurosci 19:4102–4109PubMedGoogle Scholar
  26. Rogers JL, De Santis S, See RE (2008) Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats. Psychopharmacology (Berl) 199:615–624CrossRefGoogle Scholar
  27. Ross S, Peselow E (2009) The neurobiology of addictive disorders. Clin Neuropharmacol 32:269–276PubMedCrossRefGoogle Scholar
  28. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168:3–20CrossRefGoogle Scholar
  29. Shelton KL, Beardsley PM (2008) Effect of drug-paired exteroceptive stimulus presentations on methamphetamine reinstatement in rats. Pharmacol Biochem Behav 90:434–440PubMedCrossRefGoogle Scholar
  30. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433PubMedCrossRefGoogle Scholar
  31. Willuhn I, Wanat MJ, Clark JJ, Phillips PE (2010) Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci 3:29–71PubMedCrossRefGoogle Scholar
  32. Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94(4):469–492PubMedCrossRefGoogle Scholar
  33. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191–225PubMedCrossRefGoogle Scholar
  34. Yahyavi-Firouz-Abadi N, See RE (2009) Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol Ther 124:235–247PubMedCrossRefGoogle Scholar
  35. Zheng G, Dwoskin LP, Crooks PA (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8:E682–E692PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Kristin M. Alvers
    • 1
  • Joshua S. Beckmann
    • 1
  • Guangrong Zheng
    • 2
  • Peter A. Crooks
    • 2
  • Linda P. Dwoskin
    • 2
  • Michael T. Bardo
    • 1
    • 3
  1. 1.Department of PsychologyUniversity of KentuckyLexingtonUSA
  2. 2.Department of Pharmaceutical SciencesUniversity of KentuckyLexingtonUSA
  3. 3.Department of PsychologyUniversity of KentuckyLexingtonUSA

Personalised recommendations